Apolipoprotein e genotype-specific short-term cognitive benefits of treatment with the antihypertensive nilvadipine in Alzheimer's patientsa-an open-label trial

International Journal of Geriatric Psychiatry

Volumn 27, Issue 4, 2012, Pages 415-422

  Kennelly, Sean ^a   Abdullah, Laila ^b   Kenny, Rose Anne ^a   Mathura, Venkat ^b   Luis, Cheryl A ^b   Mouzon, Benoit ^b   Crawford, Fiona ^b   Mullan, Michael ^b   Lawlor, Brian ^c  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b ROSKAMP INSTITUTE   (United States)

^c ST JAMES S HOSPITAL   (Ireland)

Author keywords

alzheimer's; antihypertensive; cognition; nilvadipine

Indexed keywords

APOLIPOPROTEIN E; NILVADIPINE;

AGED; ALZHEIMER DISEASE; ARTICLE; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; EDUCATIONAL STATUS; EXECUTIVE FUNCTION; FEMALE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; OUTCOME ASSESSMENT; SEX DIFFERENCE;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANTIHYPERTENSIVE AGENTS; APOLIPOPROTEIN E4; COGNITION; COHORT STUDIES; EXECUTIVE FUNCTION; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; NIFEDIPINE;

EID: 84858339480     PISSN: 08856230     EISSN: 10991166     Source Type: Journal    
DOI: 10.1002/gps.2735     Document Type: Article

References (42)

1. Aerssens J, Raeymaekers P, Lilienfeld S, et al,. 2001 APOE genotype: no influence on galantamine treatment efficacy nor on rate of decline in Alzheimer's disease. Dement Geriatr Cogn Disord 12: 69-77. (Pubitemid 32149710)
2. Auchus AP, Brashear HR, Salloway S, et al,. 2007. Galantamine treatment of vascular dementia: a randomized trial. Neurology 69: 448-458. (Pubitemid 47450280)
3. Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM,. 2007. Forecasting the global burden of Alzheimer's disease. Alzheimers Dement 3: 186-191. (Pubitemid 46825511)
4. Chobanian AV, Bakris GL, Black HR, et al,. 2003. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289: 2560-2572. (Pubitemid 37430158)
5. Cullen B, Fahy S, Cunningham C.J, et al,. 2005. Screening for dementia in an Irish community sample using MMSE: a comparison of norm-adjusted versus fixed cut-points. Int J Geriatr Psychiatry 20: 371-376. (Pubitemid 40590499)
6. De La Torre JC,. 2002. Alzheimer disease as a vascular disorder: nosological evidence. Stroke. 33: 1152-1162.
7. De La Torre JC,. 2008. Pathophysiology of neuronal energy crisis in Alzheimer's disease. Neurodegener Dis 5: 126-132. (Pubitemid 351347829)
8. Ercoli LM, Siddarth P, Dunkin JJ, Bramen J, Small GW,. 2003. MMSE items predict cognitive decline in persons with genetic risk for Alzheimer's disease. J Geriatr Psychiatry Neurol 16: 67-73. (Pubitemid 37409032)
9. Folstein MF, Folstein SE, Mchugh PR,. 1975. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 189-198.
10. Forette F, Seux ML, Staessen JA, et al,. 2002. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch Intern Med. 162: 2046-2052. (Pubitemid 35168212)
11. Forette F, Seux ML, Staessen JA, et al,. 1998. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 352: 1347-1351. (Pubitemid 28510916)
12. Hanyu H, Hirao K, Shimizu S, et al,. 2007a. Favourable effects of nilvadipine on cognitive function and regional cerebral blood flow on SPECT in hypertensive patients with mild cognitive impairment. Nucl Med Commun 28: 281-287. (Pubitemid 46673205)
13. Hanyu H, Hirao K, Shimizu S, et al,. 2007b. Nilvadipine prevents cognitive decline of patients with mild cognitive impairment. Int J Geriatr Psychiatry 22: 1264-1266. (Pubitemid 350285434)
14. In't Veld BA, Ruitenberg A, Hofman A, Stricker BH, Breteler MM,. 2001. Antihypertensive drugs and incidence of dementia: the Rotterdam Study. Neurobiol Aging 22: 407-412. (Pubitemid 32510912)
15. Iwasaki K, Egashira N, Takagaki Y, et al,. 2007. Nilvadipine prevents the impairment of spatial memory induced by cerebral ischemia combined with beta-amyloid in rats. Biol Pharm Bull 30: 698-701. (Pubitemid 46570991)
16. Kennelly SP, Abdullah L, Paris D, et al,. 2010. Demonstration of safety in Alzheimer's patients for intervention with an anti-hypertensive drug nilvadipine: results from a 6-week open label study. Int J Geriatr Psychiatry [Epub ahead of print].
17. Kobayashi S, Yamaguchi S, Okada K, et al,. 1992. Effect of single oral administration of nilvadipine on cerebral blood flow in chronic cerebral infarction. Angiology 43: 801-809.
18. Launer LJ, Ross GW, Petrovitch H, et al,. 2000. Midlife blood pressure and dementia: the Honolulu-Asia aging study. Neurobiol Aging 21: 49-55. (Pubitemid 30224785)
19. Lehtovirta M, Kuikka J, Helisalmi S, et al,. 1998. Longitudinal SPECT study in Alzheimer's disease: relation to apolipoprotein E polymorphism. J Neurol Neurosurg Psychiatry. 64: 742-746. (Pubitemid 28274407)
20. Lopez-Arrieta JM, Birks J,. 2002. Nimodipine for primary degenerative, mixed and vascular dementia. Cochrane Database Syst Rev. CD000147.
21. Matsuda H, Araki N, Kuji I, et al,. 2008. Effect of nilvadipine on regional cerebral blood flow in a patient with early Alzheimer disease. Clin Nucl Med. 33: 34-35.
22. Maxwell CJ, Hogan DB, Ebly EM,. 1999. Calcium-channel blockers and cognitive function in elderly people: results from the Canadian Study of Health and Aging. CMAJ 161: 501-506. (Pubitemid 29433523)
23. Mckhann G, Drachman D, Folstein M, et al,. 1984. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34: 939-944. (Pubitemid 14076461)
24. Mosconi L, Pupi A, De Leon MJ,. 2008. Brain glucose hypometabolism and oxidative stress in preclinical Alzheimer's disease. Ann N Y Acad Sci 1147: 180-195.
25. O'brien E, Coats A, Owens P, et al,. 2000. Use and interpretation of ambulatory blood pressure monitoring: recommendations of the British hypertension society. BMJ 320: 1128-1134. (Pubitemid 30213975)
26. Ogasawara K, Noda A, Yasuda S, et al,. 2003. Effect of calcium antagonist on cerebral blood flow and oxygen metabolism in patients with hypertension and chronic major cerebral artery occlusion: a positron emission tomography study. Nucl Med Commun 24: 71-76.
27. Palatini P, Frigo G, Bertolo, O, et al,. 1998. Validation of the A&D TM-2430 device for ambulatory blood pressure monitoring and evaluation of performance according to subjects' characteristics. Blood Press Monit 3: 255-260. (Pubitemid 28521776)
28. Paris D, Quadros A, Humphrey J, et al,. 2004. Nilvadipine antagonizes both Abeta vasoactivity in isolated arteries, and the reduced cerebral blood flow in APPsw transgenic mice. Brain Res 999: 53-61. (Pubitemid 38121450)
29. Roman GC, Tatemichi TK, Erkinjuntti T, et al,. 1993. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 43: 250-260. (Pubitemid 23060253)
30. Royall DR, Mahurin RK, Gray KF,. 1992. Bedside assessment of executive cognitive impairment: the executive interview. J Am Geriatr Soc 40: 1221-1226.
31. Sabbagh MN, Lynn P, Jhingran S, et al,. 1997. Correlations between SPECT regional cerebral blood flow and psychometric testing in patients with Alzheimer's disease. J Neuropsychiatry Clin Neurosci 9: 68-74. (Pubitemid 27075416)
32. Salloway S, Sperling R, Gilman S, et al,. 2009. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 73: 2061-2070.
33. Sato T, Hanyu H, Akai T, et al,. 2008. A patient with early Alzheimer's disease who showed improvement of cognitive function and cerebral perfusion by combined therapy of nilvadipine and PPAR gamma agonists. Nippon Ronen Igakkai Zasshi. 45: 428-433.
34. Seltzer B, Zolnouni P, Nunez M, et al,. 2004. Efficacy of donepezil in early-stage Alzheimer disease: a randomized placebo-controlled trial. Arch Neurol 61: 1852-1856. (Pubitemid 39612945)
35. Skoog I, Lernfelt B, Landahl S, et al,. 1996. 15-year longitudinal study of blood pressure and dementia. Lancet 347: 1141-1145. (Pubitemid 126512042)
36. Soininen H, Helkala EL, Kuikka J, et al,. 1995. Regional cerebral blood flow measured by 99mTc-HMPAO SPECT differs in subgroups of Alzheimer's disease. J Neural Transm Park Dis Dement Sect 9: 95-109.
37. Staessen JA, Celis H, Hond ED, et al,. 2002. Comparison of conventional and automated blood pressure measurements: interim analysis of the THOP trial. Treatment of Hypertension According to Home or Office Blood Pressure. Blood Press Monit 7: 61-62. (Pubitemid 34304055)
38. Visser PJ, Scheltens P, Pelgrim E, Verhey FR,. 2005. Medial temporal lobe atrophy and APOE genotype do not predict cognitive improvement upon treatment with rivastigmine in Alzheimer's disease patients. Dement Geriatr Cogn Disord 19: 126-133. (Pubitemid 40868039)
39. Weir MR, Vlachkis ND, Dequattro V, et al,. 1990. Evaluation of the clinical pharmacology of nilvadipine in patients with mild to moderate essential hypertension. J Clin Pharmacol 30: 425-437. (Pubitemid 20228345)
40. Wenham PR, Price WH, Blandell G,. 1991. Apolipoprotein E genotyping by one-stage PCR. Lancet 337: 1158-1159.
41. Zahn R, Garrard P, Talazko J, et al,. 2006. Patterns of regional brain hypometabolism associated with knowledge of semantic features and categories in Alzheimer's disease. J Cogn Neurosci 18: 2138-2151. (Pubitemid 44913365)
42. Zahn R, Juengling F, Bubrowski P, et al,. 2004. Hemispheric asymmetries of hypometabolism associated with semantic memory impairment in Alzheimer's disease: a study using positron emission tomography with fluorodeoxyglucose-F18. Psychiatry Res 132: 159-172. (Pubitemid 39643013)